Sign inJoin waitlistJoin the waitlist

Jianjun Gao

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2010–2013
Internal Medicine
University of Wisconsin School of Medicine and Public Health
2006–2010
Univ of Kansas Sch of Med
2002–2006
University of Kansas School of Medicine
1998–1999

Research

B cells and tertiary lymphoid structures promote immunotherapy response
Nature · 2020 · Co-first of 60 authors · 2,219 citations
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Cell · 2016 · First of 16 authors · 1,100 citations
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Nature Medicine · 2018 · 628 citations

Matthew Campbell
40 papers · 1 as a fellow
Amishi Shah
37 papers · 2 as a fellow
Nizar Tannir
37 papers
Pavlos Msaouel
35 papers · 21 as a fellow
Arlene Siefker-Radtke
33 papers
Omar Alhalabi
30 papers · 10 as a fellow
Padmanee Sharma
29 papers
Ashish Kamat
26 papers
Charles Guo
23 papers
Eric Jonasch
19 papers
Sangeeta Goswami
17 papers
Colin Dinney
15 papers

Grants

Illuminating the Immune Dynamics of Metastatic Renal Cell Carcinoma to Bone
National Cancer Institute · R01
PI · $579.7K · University of Tx Md Anderson Can Ctr
2026–2031
Lineage Plasticity Sensitizes FGFR3-Mutant Bladder Cancer to FGFR Inhibitors
National Cancer Institute · R01
PI · $637.5K · University of Tx Md Anderson Can Ctr
2026–2031
Dissecting Mechanism of EPHX2 Deficient Bladder Cancer and Targeting Metabolic and Immunologic Vulnerabilities
National Cancer Institute · R01
PI · $681.3K · Baylor College of Medicine
2026–2031
Decoding Tumor Metabolic and Immunologic Interactions Driving Different Biological Subtypes in Patients with Bladder Cancer.
National Cancer Institute · R01
PI · $2.5M · Baylor College of Medicine
2023–2028

Clinical trials

Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2017–2019
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery
Principal investigator · Active not recruiting · Early phase 1
M.D. Anderson Cancer Center
2017–2027